UOC
COGT icon

UBS O'Connor’s Cogent Biosciences COGT Stock Holding History

UBS O'Connor’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,442
Closed -$151K – 560
2024
Q1 		$151K Buy
+22,442
New +$139K ﹤0.01% 411

Other funds holding COGT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

UBS O'Connor's COGT Position: Q2 2024 in Review

UBS O'Connor sold out of Cogent Biosciences (COGT) in Q2 2024, closing a stake of 22,442 shares — an estimated $151K sold.

UBS O'Connor first reported a position in COGT in Q1 2024 and held it in 1 quarter. The position peaked at $151K in Q1 2024. 148 funds tracked by Wall St. Rank hold COGT as of Q2 2024.

  • UBS O'Connor reported no remaining Cogent Biosciences position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 22,442 Cogent Biosciences shares in Q2 2024, an estimated $151K.
  • UBS O'Connor first reported a position in Cogent Biosciences in Q1 2024 and held it in 1 quarter.
  • UBS O'Connor's Cogent Biosciences position peaked at $151K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.